Stewart Appelrouth is Director at AIM ImmunoTech Inc. (AIM). They have made 10 open-market trades across 2 companies since 2016, most recently 2024-12-31.
CIK 0001702626
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
10 open-market purchases totalling $248K since 2016, never a sale. Across 9 scored buys the stock is down 14.0% at ninety days, and 16.8 points behind the S&P over the same stretch.
10 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 40% | 22% |
| Avg Move | +7.6% | -1.7% | -14.0% |
| Alpha | +6.4% | -3.0% | -16.8% |
| Scored | 10 | 10 | 9 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AIM | BUY | 2024-12-02 | 2024-12-04 | $0.21 | $2K | +4.6% | +16.3% | -38.5% |
| AIM | BUY | 2024-11-20 | 2024-11-21 | $0.19 | $16K | -2.2% | -11.4% | -36.8% |
| AIM | BUY | 2024-03-15 | 2024-03-18 | $0.33 | $30K | +15.2% | +16.3% | +3.9% |
| AIM | BUY | 2023-01-03 | 2023-01-04 | $0.31 | $25K | +79.1% | +30.7% | +3.6% |
| AIM | BUY | 2021-02-25 | 2021-02-25 | $2.35 | $25K | -4.8% | -7.4% | -7.9% |
| HEB | BUY | 2019-06-21 | 2019-06-25 | $4.03 | $39K | -10.6% | -37.6% | N/A |
| HEB | BUY | 2018-11-05 | 2018-11-06 | $0.22 | $6K | -8.2% | -24.9% | -4.1% |
| HEB | BUY | 2018-07-24 | 2018-07-24 | $0.31 | $39K | -2.7% | -13.3% | -31.9% |
| HEB | BUY | 2018-04-27 | 2018-04-30 | $0.32 | $32K | -5.1% | -5.3% | -6.7% |
| HEB | BUY | 2016-08-24 | 2017-03-31 | $2.21 | $35K | +11.3% | +19.1% | -7.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.